<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00278330</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00077</org_study_id>
    <secondary_id>MCC 6637</secondary_id>
    <secondary_id>CDR0000656277</secondary_id>
    <secondary_id>R21CA115260</secondary_id>
    <secondary_id>U01CA062490</secondary_id>
    <nct_id>NCT00278330</nct_id>
  </id_info>
  <brief_title>Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia</brief_title>
  <official_title>Phase I Trial of Vorinostat (SAHA) in Combination With Alvocidib (Flavopiridol) in Patients With Relapsed, Refractory, or (Selected) Poor Prognosis Acute Leukemia or Refractory Anemia With Excess Blasts-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of flavopiridol when given&#xD;
      together with vorinostat in treating patients with relapsed or refractory acute leukemia or&#xD;
      chronic myelogenous leukemia or refractory anemia. Flavopiridol and vorinostat may cause&#xD;
      leukemia cells to look more like normal cells, and to grow and spread more slowly. Vorinostat&#xD;
      may also stop the growth of cancer cells by blocking some of the enzymes needed for cell&#xD;
      growth. Giving flavopiridol together with vorinostat may be an effective treatment for&#xD;
      leukemia or refractory anemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Determine recommended phase II doses for the combination of flavopiridol and vorinostat in&#xD;
      patients with acute leukemia, chronic myelogenous leukemia in blast crisis, or refractory&#xD;
      anemia with excess blasts-2.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the safety, toxicity, tolerability, and maximum tolerated dose of this drug&#xD;
      regimen.&#xD;
&#xD;
      II. Determine the pharmacodynamic and clinical anti-leukemic effects of this drug regimen.&#xD;
&#xD;
      III. Correlate leukemia gene expression patterns with response in patients treated with this&#xD;
      regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation study of flavopiridol.&#xD;
&#xD;
      Patients receive flavopiridol IV over 1 hour on days 1-5 and oral vorinostat three times&#xD;
      daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD for the combination of alvocidib and vorinostat, assessed by Common Toxicity Criteria version 3.0</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Blastic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Recurrent Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <condition>Refractory Anemia With Excess Blasts</condition>
  <condition>Relapsing Chronic Myelogenous Leukemia</condition>
  <condition>Untreated Adult Acute Lymphoblastic Leukemia</condition>
  <condition>Untreated Adult Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a 1-hour infusion of flavopiridol on 5 days in week 1 and vorinostat by mouth three times a day in weeks 1 and 2. Treatment may repeat every 3 weeks for as long as benefit is shown.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alvocidib</intervention_name>
    <description>Given by infusion</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>FLAVO</other_name>
    <other_name>flavopiridol</other_name>
    <other_name>HMR 1275</other_name>
    <other_name>L-868275</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>L-001079038</other_name>
    <other_name>SAHA</other_name>
    <other_name>suberoylanilide hydroxamic acid</other_name>
    <other_name>Zolinza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of one of the following:&#xD;
&#xD;
               -  Relapsed or refractory acute leukemia (acute myeloid leukemia [AML], acute&#xD;
                  lymphoblastic leukemia [ALL], or acute leukemia unclassifiable) following at&#xD;
                  least one prior systemic treatment&#xD;
&#xD;
               -  Acute leukemia in a patient 60 years or older (no requirement for prior&#xD;
                  treatment)&#xD;
&#xD;
               -  Acute leukemia that has evolved from a prior myelodysplastic syndrome&#xD;
&#xD;
               -  Chronic myelogenous leukemia (CML) in blast crisis following prior imatinib&#xD;
                  mesylate therapy&#xD;
&#xD;
               -  Refractory anemia with excess blasts-2 (RAEB-2)&#xD;
&#xD;
               -  No known CNS leukemia&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  WBC &lt; 50,000ÂµL&#xD;
&#xD;
          -  Hydroxyurea and/or leukaphereses may be used to lower WBC&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 times upper limit of normal (ULN) OR creatinine clearance &gt;= 50&#xD;
             mL/min&#xD;
&#xD;
          -  Total bilirubin =&lt; 2 times ULN&#xD;
&#xD;
          -  AST/ALT =&lt; 2.5 times ULN&#xD;
&#xD;
          -  QTc interval =&lt; 0.470 seconds&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  No other condition that would preclude study participation&#xD;
&#xD;
          -  At least 3 weeks since prior treatment (expect leukaphereses)&#xD;
&#xD;
          -  No valproic acid therapy within the past 2 weeks&#xD;
&#xD;
          -  No prior autologous or allogeneic bone marrow or stem cell transplantation&#xD;
&#xD;
          -  No hydroxyurea use within the past 24 hours&#xD;
&#xD;
          -  No concurrent treatment with other anti-cancer agents or investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Grant</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massey Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>January 16, 2006</study_first_submitted>
  <study_first_submitted_qc>January 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2006</study_first_posted>
  <last_update_submitted>April 1, 2013</last_update_submitted>
  <last_update_submitted_qc>April 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Refractory</mesh_term>
    <mesh_term>Anemia, Refractory, with Excess of Blasts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Alvocidib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

